FNDC5 and type 2 diabetes mellitus: Circulating irisin was found to be significantly reduced in long-term [8], new onset [9] and undefined [10] type 2 diabetes patients compared with non-diabetic controls, which suggested either the diabetic state itself or the metabolic condition that caused progression to type 2 diabetes is accompanied by lower circulating irisin [11].